TB038 Heterologous effects of BCG
Research type
Research Study
Full title
Evaluation of the heterologous effects of Bacille Calmette-Guerin (BCG) vaccination in healthy UK adults.
IRAS ID
170572
Contact name
Helen McShane
Contact email
Sponsor organisation
University of Oxford
Duration of Study in the UK
1 years, 6 months, 0 days
Research summary
Tuberculosis (also known as TB) is a disease caused by bacteria that continues to be a significant cause of death worldwide. BCG (Bacille Calmette-Guérin) is the only vaccine currently in use against TB. BCG works well against disease from TB in childhood, but it is not good enough at protecting against disease in adulthood. Steps are in place to develop a replacement vaccine for BCG. However, when babies are given BCG in the first few weeks of life, it has been observed that these babies appear to be protected against death from infections caused by other types of bacteria, not just TB. Our understanding of how this protection occurs is not complete. We want to gain a better understanding of how the body’s immune system reacts to BCG and in turn potentially prevents infection from other bacteria.
This study will take place at two sites, the CCVTM, Oxford and the WTCRF, Birmingham.
REC name
South Central - Oxford B Research Ethics Committee
REC reference
15/SC/0022
Date of REC Opinion
20 Jan 2015
REC opinion
Favourable Opinion